We are live on !
Find out more
Mangrove Partners Portfolio holdings
AUM
$1.52B
Turnover
63.74%
1-Year Est. Return
36.54%
This Fund
S&P 500
This Quarter Est. Return
+8.88%
1 Year Est. Return
+36.54%
3 Year Est. Return
+184.84%
5 Year Est. Return
+166.78%
10 Year Est. Return
+454.53%
AUM
$1.52B
AUM Growth
+$287M
(+23%)
Cap. Flow
+$202M
Cap. Flow % of AUM
Cap. Flow %
13.28%
Top 10 Holdings %
Top 10 Hldgs %
38.09%
Holding
626
New
199
Increased
41
Reduced
61
Closed
200
Avg Time Held
0.3
years
Top 10 Avg Time Held
0.6
years
Top 20 Avg Time Held
0.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vistance Networks Inc
VISN
|
+$101M |
| 2 |
Aptiv
APTV
|
+$37.5M |
| 3 |
Acadia Healthcare
ACHC
|
+$35.8M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$25.9M |
| 5 |
Bel Fuse Inc Class A
BELFA
|
+$25.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enova International
ENVA
|
+$49.1M |
| 2 |
Grayscale Ethereum Staking Mini ETF Shares
ETH
|
+$25.8M |
| 3 |
TripAdvisor
TRIP
|
+$10.3M |
| 4 |
Bitwise Solana Staking ETF
BSOL
|
+$8.47M |
| 5 |
Atmus Filtration Technologies
ATMU
|
+$5.65M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.15% |
| 2 | Financials | 18.28% |
| 3 | Healthcare | 14.14% |
| 4 | Consumer Discretionary | 10.53% |
| 5 | Miscellaneous | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
151
C.H. Robinson
CHRW
$15.6B
| $769K | 0.05% |
4,084
| – | – |
2026 Q1
1 quarter
|
|
152
AdaptHealth
AHCO
$1.05B
| $763K | 0.05% |
73,219
-91,742
| -56% | -$1.02M |
2026 Q1
1 quarter
|
|
153
Akebia Therapeutics
AKBA
$132M
| $760K | 0.05% |
666,954
+291,000
| +77% | +$346K |
2026 Q1
1 quarter
|
|
154
ANI Pharmaceuticals
ANIP
$1.62B
| $758K | 0.05% |
9,154
-3,764
| -29% | -$302K |
2025 Q4
2 quarters
|
|
155
Progyny
PGNY
$2.66B
| $757K | 0.05% |
+26,258
| New | +$587K |
2026 Q2
0 quarters
|
|
156
Markel Group
MKL
$24.2B
| $756K | 0.05% |
+387
| New | +$723K |
2026 Q2
0 quarters
|
|
157
Phillips 66
PSX
$103B
| $752K | 0.05% |
4,447
| – | – |
2025 Q4
2 quarters
|
|
158
Hercules Capital
HTGC
$3.01B
| $744K | 0.05% |
+47,148
| New | +$733K |
2026 Q2
0 quarters
|
|
159
TriMas Corp
TRS
$1.35B
| $737K | 0.05% |
16,365
+1,086
| +7% | +$43.2K |
2026 Q1
1 quarter
|
|
160
Core Scientific
CORZ
$4.68B
| $733K | 0.05% |
28,655
-14,806
| -34% | -$349K |
2026 Q1
1 quarter
|
|
161
US Gold Corp
USAU
$176M
| $728K | 0.05% |
+47,480
| New | +$751K |
2026 Q2
0 quarters
|
|
162
Altimmune
ALT
$321M
| $727K | 0.05% |
239,280
| – | – |
2026 Q1
1 quarter
|
|
163
TAL Education Group
TAL
$5.7B
| $724K | 0.05% |
+75,640
| New | +$795K |
2026 Q2
0 quarters
|
|
164
Lifestance Health
LFST
$5.35B
| $712K | 0.05% |
66,466
-121,244
| -65% | -$937K |
2026 Q1
1 quarter
|
|
165
DELISTED
Forte Biosciences
FBRX
| $709K | 0.05% |
33,346
+7,640
| +30% | +$181K |
2026 Q1
1 quarter
|
|
166
Scansource
SCSC
$910M
| $700K | 0.05% |
13,432
-6,113
| -31% | -$268K |
2025 Q4
2 quarters
|
|
167
Zoetis
ZTS
$34.1B
| $694K | 0.05% |
+9,652
| New | +$909K |
2026 Q2
0 quarters
|
|
168
Lineage Inc
LINE
$8.04B
| $688K | 0.05% |
15,910
| – | – |
2026 Q1
1 quarter
|
|
169
Insperity
NSP
$1.92B
| $687K | 0.05% |
+16,630
| New | +$545K |
2026 Q2
0 quarters
|
|
170
Pool Corp
POOL
$7.72B
| $679K | 0.04% |
3,159
| – | – |
2026 Q1
1 quarter
|
|
171
Tamboran Resources
TBN
$1.02B
| $673K | 0.04% |
+20,688
| New | +$741K |
2026 Q2
0 quarters
|
|
172
S&P Global
SPGI
$137B
| $669K | 0.04% |
+1,643
| New | +$694K |
2026 Q2
0 quarters
|
|
173
ADT
ADT
$7.23B
| $668K | 0.04% |
102,764
+70,547
| +219% | +$484K |
2025 Q4
2 quarters
|
|
174
HealthEquity
HQY
$8.56B
| $668K | 0.04% |
7,395
-1,403
| -16% | -$119K |
2026 Q1
1 quarter
|
|
175
Constellium
CSTM
$3.01B
| $666K | 0.04% |
20,907
+8,823
| +73% | +$285K |
2025 Q4
2 quarters
|
|
Similar funds
SPC
Mangrove Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Mangrove Partners held 626 positions worth $1.52B, up 23% from $1.24B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Mangrove Partners deployed $202M of net new capital in Q2 2026, opening 199 new positions and adding to 41 existing holdings. Its largest new stake was Aptiv: 613,392 shares worth $37.7M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 12% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was Enova International, an estimated $49.1M trimmed.
- Mangrove Partners's largest Q2 2026 buy was Aptiv: 613,392 shares worth $37.7M.
- Mangrove Partners added most to Vistance Networks Inc in Q2 2026, an estimated $101M increase.
- Mangrove Partners's biggest Q2 2026 reduction was Enova International, cutting an estimated $49.1M.
- Mangrove Partners fully exited TripAdvisor in Q2 2026, selling an estimated $10.3M.
- Mangrove Partners's ten largest holdings make up 38% of its $1.52B portfolio in Q2 2026.
- Mangrove Partners opened 199 new positions and closed 200 in Q2 2026.
- Mangrove Partners's portfolio value rose 23% quarter-over-quarter to $1.52B.
Based on Mangrove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.